• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by FSD Pharma Inc.

    7/8/24 5:16:46 PM ET
    $HUGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HUGE alert in real time by email
    6-K 1 fsd_6k.htm FORM 6-K fsd_6k.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of: June 2024

     

    Commission File Number: 001-39152

     

    FSD PHARMA INC.

    (Translation of registrant's name into English)

     

    199 Bay St., Suite 4000

    Toronto, Ontario M5L 1A9, Canada

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒   Form 40-F ☐

     

     

     

     

    INFORMATION CONTAINED IN THIS FORM 6-K REPORT

     

    Exhibit 99.1. to this Form 6-K is hereby incorporated by reference into the registrant’s Registration Statement on Form F-3 (File No. 333-276264), as amended, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

     
    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    FSD Pharma Inc.

    (Registrant)

     

     

     

     

     

    Date: July 8, 2024

    By:

    /s/ Nathan Coyle

     

     

     

    Nathan Coyle, Chief Financial Officer

     

     

     
    3

     

     

    EXHIBIT INDEX

     

    Exhibit

     

    Description

     

     

     

    99.1

     

    Notice of Annual General and Special Meeting of Shareholders to be held on July 22, 2024 and Management Information Circular dated June 10, 2024

     

     

     

    99.2

     

    Notice of Meeting and Record Date

     

     

     

    99.3

     

    Notice of Availability of Proxy Materials

     

     

     

    99.4

     

    Form of Proxy

     

     

     

    99.5

     

    Voting Instruction Form

     

     

     

    99.6

     

    Request for Financial Statements Form

     

     

     

    99.7

     

    Certificate of Abridgment

     

     
    4

     

    Get the next $HUGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HUGE

    DatePrice TargetRatingAnalyst
    More analyst ratings